Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.73 |
| ▸ | GUCY1A1 | Q02108 | 11/20 | 0.55 |
| ▸ | GUCY1B1 | Q02153 | 11/20 | 0.55 |
| ▸ | PDE5A | O76074 | 7/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29379641 | 1.00 | ADORA3 (0.73) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| Hydrochloric Acid SCHEMBL28612648 | 0.99 | ADORA3 (0.72) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL256216 | 0.95 | ADORA3 (0.69) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL5472954 | 0.92 | ADORA3 (0.67) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL12630446 | 0.92 | ADORA3 (0.67) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL31738661 | 0.91 | ADORA3 (0.66) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL5473383 | 0.91 | ADORA3 (0.66) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL18212217 | 0.91 | ADORA3 (0.70) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL5481770 | 0.90 | ADORA3 (0.64) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL2009564 | 0.90 | ADORA3 (0.68) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220211702-A1 | METHODS AND MATERIALS FOR GENDER-DEPENDENT TREATMENT OF CARDIOVASCULAR DYSFUNCTION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2022-07-07 | — | — | US | claimed |
| EP-3952992-A1 | METHODS AND MATERIALS FOR GENDER-DEPENDENT TREATMENT OF CARDIOVASCULAR DYSFUNCTION | Mayo Foundation for Medical Education and Research (US) | 2022-02-16 | — | — | EP | claimed |
| US-20190284186-A1 | PROCESS FOR PREPARING METHYL{4,6-DIAMINO-2-[1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL]PYRIMIDIN-5-YL}METHYLCARBAMATE AND ITS PURIFICATION FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND | ADVERIO PHARMA GMBH (DE) | 2019-09-19 | — | — | US | claimed |
| US-10351562-B2 | Process for preparing methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-B]pyridin-3-yl]pyrimidin-5-yl}methylcarbamate and its purification for use as pharmaceutically active compound | ADVERIO PHARMA GMBH (DE) | 2019-07-16 | — | — | US | claimed |
| EP-3498298-A1 | THE USE OF SGC STIMULATORS AND SGC ACTIVATORS ALONE OR IN COMBINATION WITH PDE5 INHIBITORS FOR THE TREATMENT OF BONE DISORDERS INCLUDING OSTEOGENESIS IMPERFECTA (OI) | Bayer AG (DE) | 2019-06-19 | — | — | EP | claimed |
| US-20180282329-A1 | PROCESS FOR PREPARING METHYL {4,6-DIAMINO-2-[1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL]PYRIMIDIN-5-YL}METHYLCARBAMATE AND ITS PURIFICATION FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND | ADVERIO PHARMA GMBH (DE) | 2018-10-04 | — | — | US | claimed |
| EP-2733142-B1 | Process for the preparation of methyl-{4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamate for use as pharmaceutically active ingredient | ADVERIO PHARMA GMBH (DE) | 2018-08-01 | — | — | EP | claimed |
| WO-2018096550-A1 | PROCESS FOR THE PREPARATION OF METHYL 4,6-DIAMINO-2-[1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL]-5-PYRIMIDINYL(METHYL)CARBAMATE AND ITS POLYMORPHS THEREOF | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2018-05-31 | — | — | WO | claimed |
| WO-2017025981-A1 | PROCESS FOR THE PREPARATION OF METHYL 4,6-DIAMINO-2-[L-(2-FHIOROBENZVR)-LH-PYRAZOLO I3,4-BLPVRIDIN-3-VN-5-PYRIMIDINYL(METHVL)CARBAMATE AND ITS POLYMORPHS THEREOF | MSN LABORATORIES PRIVATE LIMITED (IN) | 2017-02-16 | — | — | WO | claimed |
| US-8853398-B2 | Process for preparing methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b] pyridin-3-yl]pyrimidin-5-yl}methylcarbamate and its purification for use as pharmaceutically active compound | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-10-07 | — | — | US | claimed |
| US-20140288303-A1 | PROCESS FOR PREPARING METHYL METHYLCARBAMATE AND ITS PURIFICATION FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-25 | — | — | US | claimed |
| US-20130310563-A1 | PROCESS FOR PREPARING METHYL METHYLCARBAMATE AND ITS PURIFICATION FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-21 | — | — | US | claimed |
| US-20120003325-A1 | USE OF HELIUM-OXYGEN GAS MIXTURES FOR TREATING PULMONARY ARTERIAL HYPERTENSION | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-05 | — | — | US | claimed |
| US-20110130410-A1 | PROCESS FOR PREPARING METHYL METHYLCARBAMATE AND ITS PURIFICATION FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-02 | — | — | US | claimed |
| US-20110130411-A1 | PROCESS FOR PREPARING METHYL CARBAMATE AND ITS PURIFICATION FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-02 | — | — | US | claimed |
| US-7173037-B2 | Carbamate-substituted pyrazolopyridines | BAYER HEALTHCARE AG (DE) | 2007-02-06 | — | — | US | claimed |
| EP-1506193-B1 | CARBAMATE-SUBSTITUTED PYRAZOLOPYRIDINES | BAYER HEALTHCARE AG (DE) | 2006-06-21 | — | — | EP | claimed |
| EP-1506193-B9 | CARBAMATE-SUBSTITUTED PYRAZOLOPYRIDINES | ADVERIO PHARMA GMBH (DE) | 2026-02-18 | — | — | EP | disclosed |
| WO-2007009607-A1 | NOVEL USE OF ACTIVATORS AND STIMULATORS OF SOLUBLE GUANYLATE CYCLASE FOR THE PREVENTION OR TREATMENT OF RENAL DISORDERS | BAYER HEALTHCARE AG (DE) | 2007-01-25 | — | — | WO | disclosed |
| US-20060052397-A1 | Compounds for trearment of cardiovascular disorders and hypotensive agents | BAYER HEALTHCARE AG (DE) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130410-A1 | PROCESS FOR PREPARING METHYL METHYLCARBAMATE AND ITS PURIFICATION FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND | AMD1, TPMT, MMAB | ADORA3 1317/4885KCNH2 748/4885GUCY1A1 1234/4885 |
| US-20120003325-A1 | USE OF HELIUM-OXYGEN GAS MIXTURES FOR TREATING PULMONARY ARTERIAL HYPERTENSION | PTGIS, HYOU1, PTGIR | ADORA3 385/4885KCNH2 165/4885GUCY1A1 505/4885 |
| US-20180282329-A1 | PROCESS FOR PREPARING METHYL {4,6-DIAMINO-2-[1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL]PYRIMIDIN-5-YL}METHYLCARBAMATE AND ITS PURIFICATION FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND | TPMT, AMD1, DPYD | ADORA3 1331/4885KCNH2 595/4885GUCY1A1 1723/4885 |
| US-20110130411-A1 | PROCESS FOR PREPARING METHYL CARBAMATE AND ITS PURIFICATION FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND | AZI2, TPMT, KDM5B | ADORA3 2401/4885KCNH2 694/4885GUCY1A1 328/4885 |
| US-10351562-B2 | Process for preparing methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-B]pyridin-3-yl]pyrimidin-5-yl}methylcarbamate and its purification for use as pharmaceutically active compound | TPMT, AMD1, DPYD | ADORA3 1267/4885KCNH2 561/4885GUCY1A1 1683/4885 |
| US-20190284186-A1 | PROCESS FOR PREPARING METHYL{4,6-DIAMINO-2-[1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL]PYRIMIDIN-5-YL}METHYLCARBAMATE AND ITS PURIFICATION FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND | TPMT, AMD1, DPYD | ADORA3 1267/4885KCNH2 561/4885GUCY1A1 1683/4885 |
| US-20130310563-A1 | PROCESS FOR PREPARING METHYL METHYLCARBAMATE AND ITS PURIFICATION FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND | AMD1, TPMT, MMAB | ADORA3 1317/4885KCNH2 748/4885GUCY1A1 1234/4885 |
| US-20140288303-A1 | PROCESS FOR PREPARING METHYL METHYLCARBAMATE AND ITS PURIFICATION FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND | AMD1, TPMT, MMAB | ADORA3 1317/4885KCNH2 748/4885GUCY1A1 1234/4885 |
| US-20060052397-A1 | Compounds for trearment of cardiovascular disorders and hypotensive agents | PDE3A, PDE3B, PDE2A | ADORA3 221/4885KCNH2 917/4885GUCY1A1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.